Truist Lowers Elevance Health Price Target While Maintaining Positive Outlook on Healthcare Services
Truist Financial lowered its price target for Elevance Health (ELV) from $390 to $375, while maintaining a 'Buy' rating. The move was part of a broader Q1 outlook for the healthcare services sector, which Truist remains optimistic about due to stable demand, favorable reimbursement conditions, and growth from AI and automation. Evercore ISI also initiated coverage on Elevance Health with a 'In Line' rating and a $345 price target.
Tickers: $ELV
Topics: Analyst Ratings Dividend Stocks Healthcare Price Targets Stock Analysis